<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801173</url>
  </required_header>
  <id_info>
    <org_study_id>VLCKD</org_study_id>
    <nct_id>NCT04801173</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet in PCOS With Obesity and Insulin Resistance</brief_title>
  <acronym>VLCKD</acronym>
  <official_title>Effect of Very Low Calorie Ketogenic Diet on Obese and Insulin-resistant Women With Polycystic Ovary Syndrome: a Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pronokal group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the VLCKD randomized clinical trial is to demonstrate the superiority of very&#xD;
      low calorie ketogenic diet with respect to the standard low calorie diet in reducing body&#xD;
      weight and insulin resistance in obese and insulin resistant patients with Polycystic Ovary&#xD;
      Syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients coming to the Endocrinology and Diabetes Clinic of the S.Orsola hospital&#xD;
      in Bologna with the suspicion of PCOS, during the study period, will be eligible to&#xD;
      participate. In the screening phase, patients from the clinic conforming to the inclusion&#xD;
      criteria will be invited to participate in the anovulation screening phase, lasting up to 8&#xD;
      weeks, during which measurements of LH, FSH, estradiol, progesterone and a gynecologic&#xD;
      ultrasound will be done on 7th, 14th, 21st and 28th day of the presumed ovulatory cycle, or&#xD;
      at any time if amenorrhea present. Consenting participants will provide written informed&#xD;
      consent.&#xD;
&#xD;
      Following the anovulation screening, the patients will be randomized in two arms of the&#xD;
      study: 1. very low calorie ketogenic diet (VLCKD) and the 2. low calorie standard diet (LCD).&#xD;
&#xD;
      The study is open label; thus, patients and investigators will not be blinded to treatment&#xD;
      allocation due to the nature of the study intervention.&#xD;
&#xD;
      The group assigned to the VLCKD will follow the VLCKD for 8 weeks, after which they will&#xD;
      follow the LCD for the next 8 weeks.&#xD;
&#xD;
      The group assigned to the LCD will follow the LCD for the entire length of the study (16&#xD;
      weeks.)&#xD;
&#xD;
      At the start of the study, after 8 weeks and after 16 weeks, following measurements and tests&#xD;
      will be done:&#xD;
&#xD;
        1. clinical examination with the measurement of height, body mass, circumference at the&#xD;
           waist and hip level, arterial systolic and diastolic pressure, heart rate,&#xD;
           Ferriman-Gallwey and videodermoscopic evaluation of hirsutism and bioimpedance body&#xD;
           composition measurement;&#xD;
&#xD;
        2. blood will be taken for: lipid profile, hepatic transaminases, fasting glucose, fasting&#xD;
           insulin, HbA1c, potassium, sodium, urea, calcium, phosphorus, total proteins, albumins,&#xD;
           total bilirubin, uric acid, complete blood count, sex hormone binding globulin (SHBG),&#xD;
           liquid chromatography-mass spectrometry measurement of testosterone, androstenedione,&#xD;
           DHEA, 17OH-progesterone, 17OH-pregnenolone;&#xD;
&#xD;
        3. dietary interview;&#xD;
&#xD;
        4. psychological evaluation using the following questionnaires: Symptom Questionnaire, the&#xD;
           Psychosocial index and the Psychological Well-Being scales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body mass index</measure>
    <time_frame>16 weeks after the start of treatment</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body composition measured by bioimpedentiometry</measure>
    <time_frame>16 weeks after the start of the treatment</time_frame>
    <description>Fat mass and lean mass changes will be considered to estimate change in body composition and reported as %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body mass index</measure>
    <time_frame>8 weeks after the start of treatment</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition measured by bioimpedentiometry</measure>
    <time_frame>8 weeks after the start of the treatment</time_frame>
    <description>Fat mass and lean mass will be considered to estimate change in body composition and reported as %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index</measure>
    <time_frame>16 weeks after the start of the treatment</time_frame>
    <description>Fasting glucose in mmol/L and fasting insulin in mcU/mL will be combined to report Homeostasis Model Assessment Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of menstrual cycles</measure>
    <time_frame>16 weeks after the start of the treatment</time_frame>
    <description>Number of menses in the 16 weeks before will be considered to report the frequency of menstrual cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hirsutism</measure>
    <time_frame>16 weeks after the start of the treatment</time_frame>
    <description>Modified Ferriman-Gallwey score will be used to measure changes in hirsutism; the minimum and maximum values are 4 and 36 respectively; higher score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentrations of testosterone</measure>
    <time_frame>16 weeks after the start of the treatment</time_frame>
    <description>testosterone will be reported in ng/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>PCOS</condition>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Very low calorie ketogenic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low calorie diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control treatment with a low calorie standard diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Very low calorie ketogenic diet</intervention_name>
    <description>Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method</description>
    <arm_group_label>Very low calorie ketogenic diet</arm_group_label>
    <other_name>Pronokal method</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low calorie standard diet</intervention_name>
    <description>Low calorie standard diet with no specified dietary supplement addition</description>
    <arm_group_label>Low calorie diet</arm_group_label>
    <arm_group_label>Very low calorie ketogenic diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS according to the NIH criteria;&#xD;
&#xD;
          -  Body mass index (BMI) between 30 and 35 kg/m3;&#xD;
&#xD;
          -  HOMA index ≥ 3 (according to formula: (fasting glucose [mmol/L] × fasting insulin&#xD;
             [mIU/L])/22.5)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes type 1&#xD;
&#xD;
          -  Exogenous insulin or insulin analogue therapy&#xD;
&#xD;
          -  Obesity caused by endocrine disease other than PCOS&#xD;
&#xD;
          -  Obesity caused by pharmacotherapy&#xD;
&#xD;
          -  Use of a weight-loss diet in the past 3 months&#xD;
&#xD;
          -  Use of contraceptive pills in the past 3 months&#xD;
&#xD;
          -  Severe depression&#xD;
&#xD;
          -  Other psychiatric diseases&#xD;
&#xD;
          -  Alcohol or psychoactive substance abuse&#xD;
&#xD;
          -  Severe hepatic insufficiency&#xD;
&#xD;
          -  Renal calculosis&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Episodes of gout&#xD;
&#xD;
          -  Malignant neoplasia&#xD;
&#xD;
          -  Previous cardiovascular or cerebrovascular events&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Water-electrolyte imbalance&#xD;
&#xD;
          -  Any pharmacotherapy capable of interfering with glucose metabolism&#xD;
&#xD;
          -  Any pharmacotherapy capable of interfering with steroid metabolism&#xD;
&#xD;
          -  Menopause&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandra Gambineri, PhD</last_name>
    <phone>0512144628</phone>
    <phone_ext>+39</phone_ext>
    <email>alessandra.gambiner3@unibo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Srđan Pandurević, MD</last_name>
    <phone>3335710589</phone>
    <phone_ext>+39</phone_ext>
    <email>srdan.pandurevic@unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unit of Endocrinology and Prevention and Care of Diabetes, S.Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Gambineri, MD PhD</last_name>
      <phone>0512144628</phone>
      <phone_ext>+39</phone_ext>
      <email>alessandra.gambiner3@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Srdan Pandurevic, MD</last_name>
      <phone>3335710589</phone>
      <phone_ext>+39</phone_ext>
      <email>srdan.pandurevic@unibo.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017 Dec 1;32(12):2515-2521. doi: 10.1093/humrep/dex308.</citation>
    <PMID>29040529</PMID>
  </reference>
  <reference>
    <citation>Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014 Oct;171(4):P1-29. doi: 10.1530/EJE-14-0253. Epub 2014 May 21. Review.</citation>
    <PMID>24849517</PMID>
  </reference>
  <reference>
    <citation>Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011 Mar 15;335(1):30-41. doi: 10.1016/j.mce.2010.08.002. Epub 2010 Aug 11. Review.</citation>
    <PMID>20708064</PMID>
  </reference>
  <reference>
    <citation>Barrea L, Marzullo P, Muscogiuri G, Di Somma C, Scacchi M, Orio F, Aimaretti G, Colao A, Savastano S. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr Res Rev. 2018 Dec;31(2):291-301. doi: 10.1017/S0954422418000136. Epub 2018 Jul 23. Review.</citation>
    <PMID>30033891</PMID>
  </reference>
  <reference>
    <citation>González F. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin Reprod Med. 2015 Jul;33(4):276-86. doi: 10.1055/s-0035-1554918. Epub 2015 Jul 1. Review.</citation>
    <PMID>26132932</PMID>
  </reference>
  <reference>
    <citation>Volk KM, Pogrebna VV, Roberts JA, Zachry JE, Blythe SN, Toporikova N. High-Fat, High-Sugar Diet Disrupts the Preovulatory Hormone Surge and Induces Cystic Ovaries in Cycling Female Rats. J Endocr Soc. 2017 Nov 2;1(12):1488-1505. doi: 10.1210/js.2017-00305. eCollection 2017 Dec 1.</citation>
    <PMID>29308444</PMID>
  </reference>
  <reference>
    <citation>Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum in: Hum Reprod. 2019 Feb 1;34(2):388.</citation>
    <PMID>30052961</PMID>
  </reference>
  <reference>
    <citation>Matsuzaki T, Douchi T, Oki T, Ishihara O, Okagaki R, Kajihara T, Tamura M, Kotsuji F, Tajima K, Kawano M, Ishizuka B, Irahara M. Weight reduction using a formula diet recovers menstruation in obese patients with an ovulatory disorder. Reprod Med Biol. 2017 Jul 7;16(3):268-275. doi: 10.1002/rmb2.12034. eCollection 2017 Jul. Erratum in: Reprod Med Biol. 2018 Jan 16;17 (1):103.</citation>
    <PMID>29259477</PMID>
  </reference>
  <reference>
    <citation>Mehrabani HH, Salehpour S, Amiri Z, Farahani SJ, Meyer BJ, Tahbaz F. Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. J Am Coll Nutr. 2012 Apr;31(2):117-25.</citation>
    <PMID>22855917</PMID>
  </reference>
  <reference>
    <citation>Gower BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. J Nutr. 2015 Jan;145(1):177S-83S. doi: 10.3945/jn.114.195065. Epub 2014 Dec 3.</citation>
    <PMID>25527677</PMID>
  </reference>
  <reference>
    <citation>Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr Metab (Lond). 2005 Dec 16;2:35.</citation>
    <PMID>16359551</PMID>
  </reference>
  <reference>
    <citation>Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, Mariani S, Lubrano C, Poggiogalle E, Migliaccio S, Donini LM, Basciani S, Cignarelli A, Conte E, Ceccarini G, Bogazzi F, Cimino L, Condorelli RA, La Vignera S, Calogero AE, Gambineri A, Vignozzi L, Prodam F, Aimaretti G, Linsalata G, Buralli S, Monzani F, Aversa A, Vettor R, Santini F, Vitti P, Gnessi L, Pagotto U, Giorgino F, Colao A, Lenzi A; Cardiovascular Endocrinology Club of the Italian Society of Endocrinology. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2019 Nov;42(11):1365-1386. doi: 10.1007/s40618-019-01061-2. Epub 2019 May 20.</citation>
    <PMID>31111407</PMID>
  </reference>
  <reference>
    <citation>Costello MF, Misso ML, Balen A, Boyle J, Devoto L, Garad RM, Hart R, Johnson L, Jordan C, Legro RS, Norman RJ, Mocanu E, Qiao J, Rodgers RJ, Rombauts L, Tassone EC, Thangaratinam S, Vanky E, Teede HJ; International PCOS Network. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open. 2019 Jan 4;2019(1):hoy021. doi: 10.1093/hropen/hoy021. eCollection 2019.</citation>
    <PMID>31486807</PMID>
  </reference>
  <reference>
    <citation>Moreno B, Bellido D, Sajoux I, Goday A, Saavedra D, Crujeiras AB, Casanueva FF. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine. 2014 Dec;47(3):793-805. doi: 10.1007/s12020-014-0192-3. Epub 2014 Mar 4.</citation>
    <PMID>24584583</PMID>
  </reference>
  <reference>
    <citation>Goday A, Bellido D, Sajoux I, Crujeiras AB, Burguera B, García-Luna PP, Oleaga A, Moreno B, Casanueva FF. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. Nutr Diabetes. 2016 Sep 19;6(9):e230. doi: 10.1038/nutd.2016.36.</citation>
    <PMID>27643725</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Alessandra Gambineri</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ketogenic diet</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>PCOS</keyword>
  <keyword>Obesity</keyword>
  <keyword>Hyperandrogenism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

